多基因风险评分用于改进骨折风险筛查的遗传风险预测研究
本研究基于英国生物银行数据构建跟骨定量超声声速(SOS)的多基因风险评分gSOS,并在5个验证队列(N=10,522)中评估其用于骨折风险筛查的价值。结果显示,使用gSOS预筛查可分别减少37%和41%需要临床风险因素FRAX和骨密度FRAX检测的人数,同时保持较高的敏感性和特异性。
要点
- gSOS与实测SOS中度相关(r²=23.2%)。
- gSOS预筛查使CRF-FRAX和BMD-FRAX需求分别减少37%和41%。
- 预筛查后敏感性93.4%、特异性98.5%,仍保持高准确度。
核心结论
- 在骨折风险筛查中使用多基因风险评分可减少需进一步检测(包括骨密度测量)的人数,同时维持较高的敏感性和特异性以识别应推荐干预的个体。
研究设计与样本
- 在UK Biobank两个子集(341,449人和5,335人)中训练和筛选跟骨定量超声声速(SOS)的多基因风险评分,最优模型命名为gSOS。
- 在5个验证队列中使用美国国家骨质疏松指南组(NOGG)临床指南测试gSOS的筛查效用,共纳入10,522名符合条件参与者,均经全基因组基因分型并测量骨折风险因素。
- 验证队列平均年龄57至75岁,54%为女性。
主要发现
- gSOS与实测SOS强相关(r²=23.2%,95%CI 22.7%至23.7%)。
- 无遗传预筛查时,指南推荐的治疗分配敏感性和特异性分别为99.6%和97.1%,但81%人群需CRF-FRAX检测、37%需BMD-FRAX检测。
- 使用gSOS预筛查并仅对低gSOS者进一步评估后,敏感性93.4%、特异性98.5%,需CRF-FRAX和BMD-FRAX检测的比例分别减少37%和41%。
关键数值与推荐
- 参考标准为基于骨密度(BMD)的骨折风险评估工具(FRAX)评分。
- 主要结局为有无遗传预筛查时正确识别需治疗个体的敏感性和特异性。
- 次要结局为需临床风险因素FRAX(CRF-FRAX)筛查和BMD-FRAX筛查的人群比例。
临床怎么用
- 在骨折风险筛查流程中,可考虑先使用gSOS预筛查,低遗传风险者可能免于进一步临床风险因素评估和骨密度检测。
- gSOS预筛查有助于减少筛查检测数量,同时保持对需干预个体的高识别准确度。
局限性
- 研究基于以欧洲裔为主的队列。
- 研究使用骨折风险的替代指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since screening programs identify only a small proportion of the population as eligible for an intervention, genomic prediction of heritable risk factors could decrease the number needing to be screened by removing individuals at low genetic risk. We therefore tested whether a polygenic risk score for heel quantitative ultrasound speed of sound (SOS)-a heritable risk factor for osteoporotic fracture-can identify low-risk individuals who can safely be excluded from a fracture risk screening program. METHODS AND FINDINGS: A polygenic risk score for SOS was trained and selected in 2 separate subsets of UK Biobank (comprising 341,449 and 5,335 individuals). The top-performing prediction model was termed "gSOS", and its utility in fracture risk screening was tested in 5 validation cohorts using the National Osteoporosis Guideline Group clinical guidelines (N = 10,522 eligible participants). All individuals were genome-wide genotyped and had measured fracture risk factors. Across the 5 cohorts, the average age ranged from 57 to 75 years, and 54% of studied individuals were women. The main outcomes were the sensitivity and specificity to correctly identify individuals requiring treatment with and without genetic prescreening. The reference standard was a bone mineral density (BMD)-based Fracture Risk Assessment Tool (FRAX) score. The secondary outcomes were the proportions of the screened population requiring clinical-risk-factor-based FRAX (CRF-FRAX) screening and BMD-based FRAX (BMD-FRAX) screening. gSOS was strongly correlated with measured SOS (r2 = 23.2%, 95% CI 22.7% to 23.7%). Without genetic prescreening, guideline recommendations achieved a sensitivity and specificity for correct treatment assignment of 99.6% and 97.1%, respectively, in the validation cohorts. However, 81% of the population required CRF-FRAX tests, and 37% required BMD-FRAX tests to achieve this accuracy. Using gSOS in prescreening and limiting further assessment to those with a low gSOS resulted in small changes to the sensitivity and specificity (93.4% and 98.5%, respectively), but the proportions of individuals requiring CRF-FRAX tests and BMD-FRAX tests were reduced by 37% and 41%, respectively. Study limitations include a reliance on cohorts of predominantly European ethnicity and use of a proxy of fracture risk. CONCLUSIONS: Our results suggest that the use of a polygenic risk score in fracture risk screening could decrease the number of individuals requiring screening tests, including BMD measurement, while maintaining a high sensitivity and specificity to identify individuals who should be recommended an intervention.
引用
- Forgetta V, Keller-Baruch J, Forest M, et al. Development of a polygenic risk score to improve screening for fracture risk: A genetic risk prediction study. PLoS Med. 2020. PMID: 32614825. doi:10.1371/journal.pmed.1003152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。